caa a22 4500 397591829 CHVBK 20180308164940.0 cr unu---uuuuu 161202e199601 xx s 000 0 eng 10.1093/jac/37.1.133 doi (NATIONALLICENCE)oxford-10.1093/jac/37.1.133 Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of β-lactamase activity in saliva [Elektronische Daten] [R. S. Dykhuizen, D. Golder, T. M. S. Reid, I. M. Gould] One hundred and sixty-five consecutive patients (>2 years of age) with acute group A streptococcal (GAS) pharyngitis randomly received co-amoxyclav (79 patients) or phenoxymethyl penicillin (86 patients). β-Lactamase activity in saliva was determined for each patient. At follow up after seven days, tonsillar cultures from seven patients (9 6%) in the penicillin V group grew group A streptococcus; three of these patients had tonsillitis clinically. In the co-amoxiclav group these figures were three (3.8%) and two respectively (P>0.05). Within the 12 month follow up period, there were four clinical recurrences (6.1%) in the penicillin V group and seven (9.3%) in the co-amoxiclav group (P>0.1). β-Lactamase activity in the saliva was demonstrated in 29 patients (19.2%). Fourteen (74%) of 19 bacteriological failures or clinical recurrences had β-lactamase activity, versus 15 (12%) of 129 successfully treated patients (P<0.001). There is no evidence that oral co-amoxiclav is better than oral penicillin V for the first treatment of acute GAS pharyngitis, but bacteriological failure and clinical recurrence are strongly associated with the presence of β-lactamase activity in commensal flora. © 1996 The British Society for Antimicrobial Chemotherapy Original articles nationallicence Dykhuizen R. S. Infection Unit, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut Golder D. Department of Medical Microbiology, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut Reid T. M. S. Department of Medical Microbiology, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut Gould I. M. Department of Medical Microbiology, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut Journal of Antimicrobial Chemotherapy Oxford University Press 37/1(1996-01), 133-138 0305-7453 37:1<133 1996 37 jac https://doi.org/10.1093/jac/37.1.133 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.1.133 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dykhuizen R. S. Infection Unit, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut NATIONALLICENCE 700 1- Golder D. Department of Medical Microbiology, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut NATIONALLICENCE 700 1- Reid T. M. S. Department of Medical Microbiology, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut NATIONALLICENCE 700 1- Gould I. M. Department of Medical Microbiology, Aberdeen Royal Infirmary NHS Trust Forresterhill, Aberdeen AB2 2ZD, UK aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/1(1996-01), 133-138 0305-7453 37:1<133 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford